KOL Perspectives: Histologic Healing in Crohns disease
Histologic Healing in Crohns disease Market is a valuable source of guidance and direction for companies and individuals who are looking for investment or opportunities in growing Industry.
(EMAILWIRE.COM, December 06, 2018 ) This KOL Insight briefing focuses on KOLs views of Histologic Healing in Crohn’s disease.
Questions topics -
- Use of histological assessment in clinical trials and practice in Crohn’s disease
- Extrapolation of UC histology to UC
- Barriers to adoption of histology assessment in Crohn’s disease
- Impact of histological data in therapy choice in Crohn’s disease?Views on use of Geboes as an endpoint in Crohn’s disease
- Views on Phase II sub-analysis data for filgotinib
Get More Information about this report at http://www.orbisresearch.com/contacts/request-sample/2392054
Key Highlights
- Majority of KOLs state that histologic healing is not used to assess Crohn’s disease patients in clinical practice
- Main barriers to adoption of histologic healing identified by KOLs include difficulty in accessing meaningful biopsy locations, as well as lack of data surrounding histology as a treatment goal
- Data showing moderate correlation between endoscopy and histology in Phase II does not impact on views of filgotinib efficacy.
Scope
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
- 5 Europe-based & 5 N. America-based
- Interviews performed during Q2 2018
KOL data is analyzed to produce -
- Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on Histologic Healing in Crohn’s disease
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Companies Mentioned:
Gilead
Celgene
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2392054
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Questions topics -
- Use of histological assessment in clinical trials and practice in Crohn’s disease
- Extrapolation of UC histology to UC
- Barriers to adoption of histology assessment in Crohn’s disease
- Impact of histological data in therapy choice in Crohn’s disease?Views on use of Geboes as an endpoint in Crohn’s disease
- Views on Phase II sub-analysis data for filgotinib
Get More Information about this report at http://www.orbisresearch.com/contacts/request-sample/2392054
Key Highlights
- Majority of KOLs state that histologic healing is not used to assess Crohn’s disease patients in clinical practice
- Main barriers to adoption of histologic healing identified by KOLs include difficulty in accessing meaningful biopsy locations, as well as lack of data surrounding histology as a treatment goal
- Data showing moderate correlation between endoscopy and histology in Phase II does not impact on views of filgotinib efficacy.
Scope
- The insight briefing is based on Sociable Pharma’s analysis of primary research with our IBD key opinion leaders (KOLs).
In total, we conducted interviews with 10 KOLs -
- 5 Europe-based & 5 N. America-based
- Interviews performed during Q2 2018
KOL data is analyzed to produce -
- Charts summarizing KOL opinions
- Chart call-outs of key information & details
- KOL quotes
- Summary of KOL reporting trends
- Insight from Sociable Pharma's analysts
Reasons to buy
- Combines Qualitative & semi-quantitative insight from key opinion leaders on Histologic Healing in Crohn’s disease
- Includes insight & recommendations from our disease-specific healthcare analysts
- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of IBD
- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.
Companies Mentioned:
Gilead
Celgene
Make an Inquiry before Buying@ http://www.orbisresearch.com/contacts/enquiry-before-buying/2392054
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Information:
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results
Orbis Research
Hector Costello
Tel: +1 (214) 884-6817
Email us
----
This press release is posted on EmailWire.com -- a global newswire that provides Press Release Distribution Services with Guaranteed Results